Looking for research-grade compounds?
Few compounds in tb-500 peptide research are more widely discussed and more poorly defined than TB-500. Depending on which supplier’s page or forum thread you land on, the same label is said to describe a seven-amino-acid fragment, a 43-amino-acid protein, a “Wolverine” repair stack partner, and a banned substance in professional sport. Some of that is true at once; much of it conflates different molecules, different levels of evidence, and different regulatory stories.
This profile sorts it out: what TB-500 actually is, how its actin-based mechanism works, where the parent protein sits in real clinical development, what the human evidence does and doesn’t show, and why sourcing identity is the biggest practical problem a researcher faces with it. Strictly research-use-only (RUO) framing throughout — nothing here is a recommendation for use.
TB-500 is a synthetic peptide with the sequence Ac-LKKTETQ — seven amino acids (acetylated leucine-lysine-lysine-threonine-glutamate-threonine-glutamine) corresponding to residues 17–23 of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein found in virtually all mammalian cells. That seven-residue stretch is Tβ4’s actin-binding domain, the region responsible for its signature biological activity: binding monomeric actin and holding it in reserve so cells can rapidly assemble filaments when they need to move.
Tβ4 itself is one of the oldest stories in peptide science. It was first isolated from thymic tissue in the 1960s by Allan Goldstein’s research group and turned out to be the most abundant actin-binding peptide in mammalian cells — not primarily an immune factor, as the “thymosin” name suggested, but a fundamental regulator of the cell’s internal scaffolding. Decades of work mapped its roles in cell migration, wound closure, angiogenesis, and inflammation, which is why pharmaceutical developers later picked the parent protein up as a drug candidate.
Here is where it gets messy, and where identity verification matters. “TB-500” is a trade name that has been applied to both the seven-residue fragment and, by some suppliers historically, the full-length 43-residue Tβ4 protein. The two are very different molecules — the fragment has a molecular weight around 889 daltons; the full-length protein around 4,963 daltons. A certificate of analysis with mass-spectrometry identity data tells you which one is actually in the vial, which is why knowing how to read a COA is not optional for this compound: the mass result is the identity.
For the rest of this article, “TB-500” means the synthetic LKKTETQ fragment — the compound sold under that name in research channels.
Unlike peptides that act through a receptor and a signaling cascade, TB-500’s proposed activity starts with the cell’s structural hardware.
Actin exists in a dynamic equilibrium between monomeric G-actin and filamentous F-actin. Cell movement — toward a wound, through tissue, into a repair site — requires constant, rapid reorganization of that equilibrium: filaments disassemble and reassemble as the cell crawls. Tβ4 binds single G-actin molecules and sequesters them, keeping a ready pool available so filaments can be built on demand. The LKKTETQ region carries that actin-binding function, and cell-free studies of the fragment characterize G-actin binding with dissociation constants in the low micromolar range (Kd ~0.5–2 µM, 1:1 stoichiometry by isothermal titration calorimetry), consistent with direct occupancy of the actin monomer surface.
The downstream logic: by modulating the G-actin/F-actin balance, the fragment is theorized to influence cytoskeletal remodeling and therefore cell motility — migration, adhesion, and morphological change that underpin tissue reorganization during repair. Preclinical reports have associated the LKKTETQ domain with matrix metalloproteinase expression, keratinocyte and endothelial cell migration, collagen deposition, and wound closure in animal models.
The literature also describes additional, less direct effects attributed to Tβ4 biology: activation of Akt survival signaling through the focal adhesion complex (inhibiting programmed cell death in stressed cells), and modulation of inflammatory cytokines and chemokines in preclinical models. After injury, Tβ4 is released by platelets and macrophages at the damage site to initiate the repair cascade — the exogenous fragment is theorized to amplify a response the body already mounts.
The honest framing: the actin mechanism is the best-characterized part of this story. The downstream repair, survival, and anti-inflammatory effects are associations in preclinical models, not established human pharmacology — and the fragment’s activity profile should not be assumed identical to the full-length protein’s, which carries additional functional domains absent from LKKTETQ.
This is the single most useful distinction in the field, because almost all of the “human trial” language around TB-500 actually belongs to the parent protein:
| Feature | TB-500 (fragment) | Thymosin Beta-4 (full length) |
|---|---|---|
| Length | 7 amino acids (Ac-LKKTETQ) | 43 amino acids |
| Molecular weight | ~889 Da | ~4,963 Da |
| Biological breadth | Actin-binding domain only | Actin binding + additional functional domains |
| Human clinical trials | None of the fragment itself | Multiple (see below) |
| FDA approval | None | None |
| Drug-development programs | None advanced | RegeneRx RGN-259, RGN-137, RGN-352 |
Keeping these two molecules separate is what lets a researcher read the literature honestly. Everything below about clinical trials belongs to the right-hand column.
Because TB-500 is marketed as “the Tβ4 fragment,” the parent’s development history is relevant context — with the caveat that none of it validates the fragment.
RegeneRx Biopharmaceuticals has spent nearly two decades advancing Tβ4 through the clinic:
Results across these programs have been mixed; none has produced an approved drug. But the program matters for researchers because it establishes two things: Tβ4’s safety signals in humans across ophthalmic and dermal formulations, and the regulatory reality that even the best-studied member of this peptide family is not an approved medicine. The fragment sits several rungs below that — no human safety data, no dose-finding, no efficacy data of any kind.
The two compounds are constantly discussed together — the online “Wolverine stack” pairs TB-500 with BPC-157 — so a direct comparison is worth making. (Our BPC-157 research profile covers the other half of the pairing in depth.)
| Feature | TB-500 | BPC-157 |
|---|---|---|
| Origin | Thymosin beta-4 fragment | Gastric protein fragment |
| Length | 7 amino acids | 15 amino acids |
| Lead mechanisms (preclinical) | G-actin sequestration, cell migration | VEGFR2/angiogenesis, nitric oxide modulation |
| Evidence depth | Thin; parent protein has human data | Deeper preclinical; first human RCT registered Sept 2026 |
| FDA approval | None | None |
| WADA status | Prohibited (S2, by name) | Prohibited |
The pairing’s logic is legible — angiogenic signaling plus cell-migration machinery looks like a broader repair program than either alone — but the combination has never been tested in a controlled human trial. The nickname is community slang, not science. Our peptide slang glossary decodes more of the vocabulary researchers encounter in these discussions.
The regulatory picture is straightforward but frequently blurred by vendor marketing:
As a lyophilized peptide, TB-500 follows standard handling: store cold, protect from moisture, minimize freeze-thaw cycling of reconstituted material. Our peptide storage best practices lay out the full protocol — the compound’s stability is unremarkable, which is precisely why handling discipline matters: nothing about it compensates for sloppy storage.
The bigger lab consideration is identity. Because “TB-500” has historically labeled two different molecules, and because the RUO market’s quality variance is an open secret, a third-party certificate of analysis with HPLC purity and mass-spec identity confirmation is non-negotiable for this compound specifically. The mass-spec result (~889 Da vs. ~4,963 Da) is the single most informative line on the page. Apex’s third-party COA testing program exists for exactly this reason: when the label has been ambiguous, the data is the identity. Researchers comparing lots should also know how to read a certificate of analysis beyond the headline purity number.
Is TB-500 FDA approved?
No — not for any indication, and neither is its parent protein thymosin beta-4. The RegeneRx clinical programs are investigational and have not produced an approved drug.
Is TB-500 the same as thymosin beta-4?
Not necessarily. Tβ4 is the 43-amino-acid parent protein; TB-500 as sold in research channels is usually the seven-residue LKKTETQ fragment of its actin-binding domain. Some products labeled TB-500 have historically contained full-length Tβ4 instead — the COA’s mass result distinguishes them.
Why is it called the “Wolverine” peptide?
Community slang, usually applied to the TB-500 + BPC-157 pairing, referencing a reputation for tissue-repair research. It is not a scientific, regulatory, or commercial term.
Is TB-500 banned in sport?
Yes. WADA lists thymosin beta-4 and its derivatives including TB-500 on the prohibited list at all times.
Is there any human data on TB-500 itself?
No published human trials of the fragment exist. All clinical work in this family belongs to full-length thymosin beta-4 formulations (RegeneRx’s eye drop, dermal gel, and injectable programs), and fragment activity should not be inferred from parent-protein results.
What should I verify before sourcing TB-500 for research?
A third-party COA with HPLC purity and mass-spec identity confirmation — specifically the mass result, which resolves the fragment-vs-full-length ambiguity.
TB-500 is one of the most honestly interesting — and honestly thinnest — stories in research-peptide science. The actin mechanism is real biology, well described at the molecular level: a seven-residue sequence that binds actin monomers and influences the cytoskeletal dynamics cells need to move and reorganize. The parent protein has a genuine, multi-indication clinical program behind it. But between those two facts lies the gap that matters: no human safety data, no dose-finding, no efficacy evidence for the fragment itself, and a market where the label has sometimes described the wrong molecule. The responsible position is the evidence-based one — genuine mechanism, no human proof, verify the identity, strictly research use.
Related in the Apex shop: TB-500 research peptide — supplied strictly for laboratory research use.
Research Use Only disclaimer: TB-500 is an investigational compound sold strictly for laboratory research purposes. It is not approved by the FDA or any other regulator for any use, has not been evaluated for safety or efficacy in humans or animals, and is not intended for human or veterinary use. Nothing in this article constitutes medical advice.
Selank peptide research starts with an unusual origin story. Most research peptides begin as fragments of a hormone or growth
Retatrutide Peptide Research: The Triple Agonist, TRIUMPH Trials and FDA Status Retatrutide peptide research is where incretin science stopped adding
Sermorelin Peptide Research: GHRH(1-29), GH Pulses and FDA History Sermorelin peptide research occupies an unusual place in the peptide literature:
